Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery

BioImpacts

Volumn 5, Issue 2, 2015, Pages 103-111

  Jafari, Samira ^a,b   Dizaj, Solmaz Maleki ^a,b   Adibkia, Khosro ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cell penetrating peptides; Conjugation; Dendrimer; Nanoparticles; Targeted drug delivery; Translocation

Indexed keywords

ACTIVATABLE CELL PENETRATING PEPTIDE; ANTENNAPEDIA PROTEIN; BOVINE SERUM ALBUMIN; CELL PENETRATING PEPTIDE; CELL PENETRATING PEPTIDE DENDRIMER; CHITOSAN; DOXORUBICIN; GOLD NANOPARTICLE; INSULIN; LIPID NANOPARTICLE; MACROGOL; NANOCARRIER; NANOPARTICLE; NEUROPILIN 1; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; PENETRATIN; PLASMID DNA; POLYLACTIC ACID; QUANTUM DOT; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; DEGENERATIVE DISEASE; DRUG CLASSIFICATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; INTERNALIZATION; NANOPHARMACEUTICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SURFACE CHARGE;

EID: 84930392449     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.15171/bi.2015.10     Document Type: Review

References (102)

1. Derossi D. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998; 8: 84-7.
2. Schwarze S, Dowdy S. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000; 21: 45-8.
3. Lindgren M, Hällbrink M, Prochiantz A, Langel Ü. Cell-penetrating peptides. Trends Pharmacol Sci 2000; 21: 99-103. doi: 10.1016/ S0165-6147(00)01447-4.
4. Lindgren M, Langel U. Classes and prediction of cell-penetrating peptides. Methods Mol Biol 2011; 683: 3-19.
5. Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 2005; 57: 529-45. doi: 10.1016/j.addr.2004.10.010.
6. Silhol M, Tyagi M, Giacca M, Lebleu B, Vivès E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Europ J Biochem 2002; 269: 494-501. doi: 10.1046/j.0014-2956.2001.02671.x.
7. Jones S, Christison R, Bundell K, Voyce C, Brockbank S, Newham PB. Characterisation of cell-penetrating peptide-mediated peptide delivery. British J Pharmacol 2005; 145: 1093-102. doi: 10.1038/ sj.bjp.0706279.
8. Deshayes S, Morris M, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005; 62: 1839-49. doi: 10.1007/s1008-005-5109-0.
9. Adibkia K, Barzegar-Jalali M, Nokhodchi A, Siahi Shadbad M, Omidi Y, Javadzadeh Y. A review on the methods of preparation of pharmaceutical nanoparticles. Pharm Sci 2010; 15: 303-14.
10. Adibkia K, Javadzadeh Y, Dastmalchi S, Mohammadi G, Niri F, Alaei-Beirami M. Preparation and physicochemical characterization. Colloids and Surf B: Biointerfaces 2011; 83: 155-59.
11. Mohammadi G, Nokhodchi A, Barzegar-Jalali M, Lotfipour F, Adibkia K, Ehyaei N. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids and Surf B: Biointerfaces 2011; 88: 39-44. doi: 10.1016/j.colsurfb.2011.05.050.
12. Adibkia K, Omidi Y, Siahi M, Javadzadeh A, Barzegar-Jalali M, Barar J. Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther 2007; 23: 421-32. doi: 10.1089/jop.2007.0039.
13. El-Andaloussi S, Langel U. Cell-penetrating peptides: mechanisms and applications. Curr Pharm Des 2005; 11: 3597-611. doi: 10.2174/138161205774580796.
14. Maleki Dizaj S, Jafari S, Yari Khosroushahi A. A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res Let 2014; 9: 252-61.
15. Maus L, Dick O, Bading H, Spatz J, Fiammengo R. Conjugation of Peptides to the Passivation Shell of Gold Nanoparticles for Targeting of Cell-Surface Receptors. ACS Nano 2010; 4: 6617-28. doi: 10.1021/nn101867w.
16. Park H, Tsutsumi H, Mihara H. Cell penetration and cellselective drug delivery using a-helix peptides conjugated with gold nanoparticles. Biomaterials 2013; 34: 4872-79. doi: 10.1016/j. biomaterials.2013.03.049.
17. Chen B, Liu Q, Zhang Y, Xu L, Fang X. Transmembrane delivery of the cell-penetrating peptide conjugated semiconductor quantum dots. Langmuir 2008; 24: 11866-71. doi: 10.1021/la802048s.
18. Liu B, Huang Y, Winiarz J, Chiang H, Lee H. Intracellular delivery of quantum dots mediated by a histidine-and argininerich HR9 cell-penetrating peptide through the direct membrane translocation mechanism. Biomaterials 2011; 32: 3520-37. doi: 10.1016/j.biomaterials.2011.01.041.
19. Wei Y, Yin G, Ma C, Huang Z, Chen X, Liao X. Synthesis and cellular compatibility of biomineralized Fe3O4 nanoparticles in tumor cells targeting peptides. Colloids and Surf B: Biointerfaces 2013; 107: 180-88. doi: 10.1016/j.colsurfb.2013.01.058.
20. Wanga C, Qiaoa L, Zhanga Q, Yanb H, Liu K. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles through direct chemisorption of FITC-Tat-PEG600-b-poly(glycerol monoacrylate). Int J Pharm 2012; 430: 372-80. doi: 10.1016/j. ijpharm.2012.04.035.
21. Song H, Yang J, Lo S, Wang Y, Fan W, Tang X. Gene transfer using selfassembled ternary complexes of cationic magnetic nanoparticles, plasmid DNA and cell-penetrating Tat peptide. Biomaterials 2010; 31: 769-78. doi: 10.1016/j.biomaterials.2009.09.085.
22. Smith C, Fuente J, Pelaz B, Furlani E, Mullin M. The effect of static magnetic fields and tat peptides on cellular and nuclear uptake of magnetic nanoparticles.Biomaterials 2010; 31: 4392-400. doi: 10.1016/j.biomaterials.2010.01.096.
23. Jiang Q, Lai L, Shen J, Wang Q, Xu F. Gene delivery to tumor cells by cationic polymeric nanovectors coupled to folic acid and the cell-penetrating peptide octaarginine. Biomaterials 2011; 32: 7253-62. doi: 10.1016/j.biomaterials.2011.06.015.
24. Jiang T, Zhang Z, Zhang Y, Lv H, Zhou J, Li C. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012; 33: 9246-58. doi: 10.1016/j. biomaterials.2012.09.027.
25. Chen J, Li S, Shen Q. Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. Europ J Pharm Sci 2012; 47: 430-43. doi: 10.1016/j. ejps.2012.07.002.
26. Ouahab A, Cheraga N, Onoja V, Shen Y, Tu J. Novel pH-sensitive charge-reversal cell penetrating peptide conjugated PEG-PLA micelles for docetaxel delivery: In vitro study. Int J Pharm 2014; 466: 233-45. doi: 10.1016/j.ijpharm.2014.03.009.
27. Donghua L, Lili W, Zhihong L, Cai Z, Na Z. Preparation, characterization, and in vitro evaluation of docetaxel-loaded poly(lactic acid)-poly(ethylene glycol) nanoparticles for parenteral drug delivery. J Biomed Nanotechnol 2010; 6: 675-82. doi: 10.1166/ jbn.2010.1160.
28. Asai T, Tsuzuku T, Takahashi S, Okamoto A, Dewa T, Nango M. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery. Biochem Biophys Res Commun 2014; 444: 599-604. doi:10.1016/j.bbrc.2014.01.107.
29. Pozo-Rodríguez A, Pujals S, Delgado D, Solinís M, Gascón A, Giralt E, et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J Control Release 2009; 133: 52-9. doi: 10.1016/j.jconrel.2008.09.004.
30. Rhee M, Davis P. Mechanism of uptake of C105Y, a novel cellpenetrating peptide. J Biol Chem 2006; 281: 1233-40. doi: 10.1074/jbc.M509813200.
31. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 2005; 102: 247-53. doi: 10.1016/j.jconrel.2004.10.018.
32. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cellpenetrating peptides for medical and biologicalapplications. Adv Drug Deliv Rev 2009; 61: 953-64. doi: 10.1016/j.addr.2009.06.001.
33. Deshayes S, Heitz A, Morris MC, Charnet P, Divita G, Heitz F. Insight into the mechanism of internalization of the cellpenetrating carrier peptide Pep-1 through conformationalanalysis. Biochemistry 2004; 43: 1449-57. doi: 10.1021/bi035682s.
34. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery systemMPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003; 31: 2717-24. doi: 10.1093/nar/gkg385.
35. Deshayes S, Morris M, Divita G, Heitz F. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005; 62: 1839-49. doi: 10.1007/s00018-005-5109-0.
36. Snyder E, Dowdy S. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv 2005; 2: 43-51. doi: 10.1517/17425247.2.1.43.
37. Wender P, Galliher W, Goun E, Jones L, Pillow T. The Design of Guanidiniumrich Transporters and Their Internalization Mechanisms. Adv Drug Deliv Rev 2008; 60: 452-72. doi: 10.1016/j. addr.2007.10.016.
38. Polanco C, Samaniego J, Castanon-Gonzalez J, Buhse T, Sordo M. Characterization of a possible uptake mechanism of selective antibacterial peptides. Acta Biochim Pol 2013; 60: 629-33.
39. Wu X, Gehring W. Cellular uptake of the Antennapedia homeodomain polypeptide by macropinocytosis. Biochem Biophys Res Commun 2014; 443: 1136-40. doi: 10.1016/j.bbrc.2013.12.062.
40. Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012; 161: 505-22. doi: 10.1016/j. jconrel.2012.01.043.
41. Nitta S, Numata K. Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int J Mol Sci 2013; 14: 1629-54. doi: 10.3390/ijms14011629.
42. Akinfieva O, Nabiev I, Sukhanova A. New directions in quantum dot-based cytometry detection of cancer serum markers and tumor cells. Crit Rev Oncol/Hematol 2013; 86: 1-14. doi: 10.1016/j. critrevonc.2012.09.004.
43. Hild W, Breunig M, Goepferich A. Quantum dots-Nano-sized probes for the exploration of cellular and intracellular targeting. Europ J Pharm Biopharm 2008; 68: 153-68. doi: 10.1016/j. ejpb.2007.06.009.
44. Liu R, Huang Y, Aronstam R. Intracellular Delivery of Nanoparticles and DNAs by IR9 Cell-penetrating Peptides. PLoS One 2013; 8: 64205-17. doi: 10.1371/journal.pone.0064205.
45. Wang C, Qiao L, Zhang Q, Yan H, Liu K. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles through direct chemisorption of FITC-Tat-PEG600-b-poly(glycerol monoacrylate). Int J Pharm 2012; 430: 372-80. doi: 10.1016/j. ijpharm.2012.04.035.
46. Yan W, Guangfu Y, Chuying M, Zhongbing H, Xianchun C, Xiaoming L, et al. Synthesis and cellular compatibility of biomineralized Fe3O4 nanoparticles in tumor cells targeting peptides. Colloids and Surf B: Biointerfaces 2013; 107: 180-88. doi: 10.1016/j.colsurfb.2013.01.058.
47. Song H, Yang J, Lo S, Wang Y, Fan W, Tang X, et al. Gene transfer using self-assembled ternary complexes of cationic magnetic nanoparticles, plasmid DNA and cell-penetrating Tat peptide. Biomaterials 2010; 31: 769-78. doi: 10.1016/j. biomaterials.2009.09.085.
48. Wang C, Qiao L, Zhang Q, Yan H, Liu K. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles through direct chemisorption of FITC-Tat-PEG600-b-poly(glycerol monoacrylate). Int J Pharm 2012; 430: 372-80. doi: 10.1016/j. ijpharm.2012.04.035.
49. Silvia Cavalli S, Carbajo D, Acosta M, Lope-Piedrafita S, Candiota A. Efficient c-amino-proline-derived cell penetrating peptide- superparamagnetic iron oxide nanoparticle conjugates via anilinecatalyzed oxime chemistry as bimodal imaging nanoagentsw. Chem Commun 2012; 48: 5322-24. doi: 10.1039/C2CC17937G.
50. Egusa S, Ebrahem Q, Mahfouz R, Saunthararajah Y. Ligand exchange on gold nanoparticles for drug delivery and enhanced therapeutic index evaluated in acute myeloid leukemia models. Exp Biol Med 2014; 30: 1553-70. doi: 10.1177/1535370214536648.
51. Shin MC, Zhang J, Min KA, Lee K, Byun Y, David AE, et al. Cellpenetrating peptides: Achievements and challenges in application for cancer treatment. Journal of Biomedical Materials Research Part A 2014; 102: 575-87. doi: 10.1002/jbm.a.34859.
52. You J, Zhou J, Zhou M, Liu Y, Robertson J, Liang D. Pharmacokinetics, clearance, and biosafety of polyethylene glycolcoated hollow gold nanospheres. Part Fibre Toxicol 2014; 11: 26-33.
53. Wang C, Ravi S, Garapati U, Das M, Howell M, Mallela J. Multifunctional Chitosan Magnetic-Graphene (CMG) Nanoparticles: a Theranostic Platform for Tumor-targeted Codelivery of Drugs, Genes and MRI Contrast Agents. J Mater Chem B Mater Biol Med 2013; 1: 4396-405. doi: 10.1039/C3TB20452A.
54. Fan B, Xing Y, Zheng Y, Sun C, Liang G. pH-responsive thiolated chitosan nanoparticles for oral low-molecular weight heparin delivery: in vitro and in vivo evaluation. Drug Deliv 2014; 28: 1-10. doi: 10.3109/10717544.2014.909908.
55. Chaubey P, Patel R, Mishra B. Development and optimization of curcumin-loaded mannosylated chitosan nanoparticles using response surface methodology in the treatment of visceral leishmaniasis. Expert Opin Drug Deliv 2014; 29: 1-19. doi: 10.1517/17425247.2014.917076.
56. Battogtokh G, Ko Y. Self-assembled Chitosan-Ceramide Nanoparticle for Enhanced Oral Delivery of Paclitaxel. Pharm Res 2014; 14: 14-8. doi: 10.1007/s11095-014-1395-2.
57. Layek B, Singh J. Cell penetrating peptide conjugated polymeric micelles as a high performance versatile nonviral gene carrier. Biomacromolecules 2013; 14: 4071-81. doi: 10.1021/bm401204n.
58. Li G, Simon M, Cancel L, Shi Z, Ji X, Tarbell J. Permeability of endothelial and astrocyte cocultures: in vitro blood-brain barrier models for drug delivery studies. Ann Biomed Eng 2010; 38: 2499-511. doi: 10.1007/s10439-010-0023-5.
59. Banks W. Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers 2008; 90: 589-94. doi: 10.1002/bip.20980.
60. Popov M, Abu Hammad I, Bachar T, Grinberg S, Linder C, Stepensky D. Delivery of analgesic peptides to the brain by nanosized bolaamphiphilic vesicles made of monolayer membranes. Eur J Pharm Biopharm 2013; 85: 381-89. doi: 10.1016/j.ejpb.2013.06.005.
61. Demeule M, Beaudet N, Regina A, Besserer-Offroy E, Murza A, Tetreault P. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J Clin Invest 2014; 124: 1199-213.
62. Xia H, Gao X, Gu G, Liu Z, Hu Q, Tu Y. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm 2012; 436: 840-50. doi: 10.1016/j.ijpharm.2012.07.029.
63. Joo M, Yhee J, Kim S, Kim K. The potential and advances in RNAi therapy: Chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers. J Control Release 2014; 24: 333-37. doi: 10.1016/j.jconrel.2014.05.030.
64. Fu G, Pan J, Lin N, Hu H, Tang W, Xu J, et al. siRNA Against KIR3DL1 as a Potential Gene Therapeutic Agent in Controlling HIV-1 Infection. Viral Immunol 2014; 16: 16-22. doi: 10.1089/ vim.2013.0126.
65. Tang Z, Zhou Y, Sun H, Li D, Zhou S. Biodegradable magnetic calcium phosphate nanoformulation for cancer therapy. Eur J Pharm Biopharm 2014. doi: 10.1016/j.ejpb.2014.01.003.
66. Lee S, Castagner B, Leroux J. Is there a future for cell-penetrating peptides in oligonucleotide delivery? Eur J Pharm Biopharm 2013; 85: 5-11. doi: 10.1016/j.ejpb.2013.03.021.
67. Jirka S, Heemskerk H, Tanganyika-de Winter C, Muilwijk D, Pang K, de Visser P. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice. Nucleic Acid Ther 2014; 24: 25-36. doi: 10.1089/nat.2013.0448.
68. Rytkonen J, Arukuusk P, Xu W, Kurrikoff K, Langel U, Lehto V. Porous silicon-cell penetrating peptide hybrid nanocarrier for intracellular delivery of oligonucleotides. Mol Pharm 2014; 11: 382-90. doi: 10.1021/mp4002624.
69. Astriab-Fisher A, Sergueev D, Fisher M, Shaw B. Conjugates of antisense oligonucleotides with the TAT and antennapedia cellpenetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res 2002; 19: 744-54. doi: 10.1023/A:1016136328329.
70. Morishita M, Kamei N, Ehara J, Isowa K, Takayama K. A novel approach using functional peptides for efficient intestinal absorption. J Control Release 2007; 118: 177-84. doi: 10.1016/j. jconrel.2006.12.022.
71. Lee S, Castagner B, Leroux JC. Is there a future for cell-penetrating peptides in oligonucleotide delivery? Eur J Pharm Biopharm 2013; 85: 5-11. doi: 10.1016/j.ejpb.2013.03.021.
72. Noriyasu K, Mariko M, Kozo T. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/ protein absorption using cell-penetrating peptides. J Control Release 2009; 136: 179-86. doi: 10.1016/j.jconrel.2009.02.015.
73. Heng B, Cao T. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: Potential advantages over antibodies expressed within the intracellular environment (Intrabody). Med Hypotheses 2005; 64: 1105-8. doi: 10.1016/j. mehy.2005.01.011.
74. Chen L, Liu J, Yu X, He M, Pei X, Tang Z. The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials 2008; 29: 4170-76. doi: 10.1016/j.biomaterials.2008.07.025.
75. Nida D, Rahman M, Carlson K, Richards-Kortum R, Follen M. Fluorescent nanocrystals for use in early cervical cancer detection. Gynecol Oncol 2005; 99: 89-94. doi: 10.1016/j.ygyno.2005.07.050.
76. Xiao Y, Gao X, Taratula O, Treado S, Urbas A, Holbrook R. Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells. BMC cancer 2009; 9: 351-61. doi: 10.1186/1471-2407-9-351.
77. Marches R, Mikoryak C, Wang RH, Pantano P, Draper R, Vitetta E. The importance of cellular internalization of antibody-targeted carbon nanotubes in the photothermal ablation of breast cancer cells. Nanotechnology 2011; 22: 095101-111. doi: 10.1088/0957-4484/22/9/095101.
78. Huang X, Jain P, El-Sayed I, El-Sayed M. Gold nanoparticles:interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine 2007; 2: 681-93. doi: 10.2217/17435889.2.5.681.
79. Kumari A, Yadav S, Yadav S. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surf B: Biointerfaces 2010; 75: 1-18. doi: 10.1016/j.colsurfb.2009.09.001.
80. Zeng Z, Hoshino Y, Rodriguez A, Yoo H, Shea K. Synthetic polymer nanoparticles with antibody-like affinity for a hydrophilic peptide. ACS Nano 2009; 4: 199-204. doi: 10.1021/nn901256s.
81. Jeyarajan S, Xavier J, Rao N, Gopal V. Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein. Int J Nanomedicine 2010; 5: 725-33.
82. Kobayashi N, Niwa M, Hao Y, Yoshida T. Nucleolar localization signals of LIM kinase 2 function as a cell-penetrating peptide. Protein Pept Lett 2010; 17: 1480-88.
83. Montrose K, Yang Y, Sun X, Wiles S, Krissansen GW. Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs. Scientific Reports 2013; 3: 1661. doi: 101038/srep01661.
84. Malhotra M, Tomaro-Duchesneau C, Saha S, Kahouli I, Prakash S. Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. International journal of Nanomedicine 2013; 8: 2041.
85. Caminade A, Laurent R, Majoral J. Characterization of Dendrimers. Adv Drug Delivery Rev 2005; 57: 2130-46. doi: 10.1016/j.addr.2005.09.011.
86. Olson E, Jiang T, Aguilera T, Nguyen Q, Ellies L, Scadeng M. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. MProc Natl Acad Sci U S A 2010; 107: 4311-16. doi: 10.1073/ pnas.0910283107.
87. Faust A, Waschkau B, Waldeck J. synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases. Bioconjug Chem 2009; 20: 904-12. doi: 10.1021/bc8004478.
88. Schafers M, Schober O, Hermann S. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques. J Nucl Med 2010; 51: 663-66. doi: 10.2967/jnumed.109.065698.
89. Liu Y, Ran R, Chen J, Kuang Q, Tang J, Mei L. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 2014; 35: 4835-47. doi: 10.1016/j. biomaterials.2014.02.031.
90. Xia H, Gu G, Hu Q, Liu Z, Jiang M. Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug. Bioconjugate chemistry 2013; 24: 419-30. doi: 10.1021/bc300520t.
91. Medina S, El-Sayed M. Dendrimers as Carriers for Delivery of Chemotherapeutic Agents. Chem Rev 2009; 109: 3141-57. doi: 10.1021/cr900174j.
92. Gillies E, Frechet J. Dendrimers and Dendritic Polymers in Drug Delivery. Drug Discov Today 2005; 10: 35-43. doi: 10.1016/S1359-6446(04)03276-3.
93. Martin A, Bernas L, Rutt B, Foster P. Enhanced Cell Uptake of Superparamagnetic Iron Oxide Nanoparticles Functionalized with Dendritic Guanidines. Bioconjugate chemistry 2008; 19: 2375-84. doi: 10.1021/bc800209u.
94. Zhao J, Zhou R, Fu X, Ren W. Cell-Penetrable Lysine Dendrimers for Anti-Cancer Drug Delivery: Synthesis and Preliminary Biological Evaluation. Arch Pharm Chem Life Sci 2014; 347: 1-9. doi: 10.1002/ardp.201300415.
95. McCarthy HO, McCaffrey J, McCrudden CM, Zholobenko A, Ali AA, McBride JW, et al. Development and characterization of selfassembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. Journal of Controlled Release 2014; 189: 141-9. doi: 10.1016/j.jconrel.2014.06.048.
96. Copolovici DM, Langel K, Eriste E, Langel Ul. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 2014; 8: 1972-94. doi: 10.1021/nn4057269.
97. Jafari M, Xu W, Pan R, Sweeting CM, Karunaratne DN, Chen P. Serum stability and physicochemical characterization of a novel amphipathic peptide C6M1 for siRNA delivery. PloS One 2014; 9: e97797. doi: 10.1371/journal.pone.0097797.
98. Fei L, Yap LP, Conti PS, Shen WC, Zaro JL. Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidineglutamate co-oligopeptide. Biomaterials 2014; 35: 4082-7. doi: 10.1016/j.biomaterials.2014.01.047.
99. Ryu JS, Kuna M, Raucher D. Penetrating the cell membrane, thermal targeting and novel anticancer drugs: the development of thermally targeted, elastin-like polypeptide cancer therapeutics. Therapeutic Delivery 2014; 5: 429-45. doi: 10.4155/tde.14.14.
100. Kadonosono T, Yamano A, Goto T, Tsubaki T, Niibori M, Kuchimaru T, et al. Cell penetrating peptides improve tumor delivery of cargos through Neuropilin-1-dependent extravasation. Journal of Controlled Release 2015. doi: 10.1016/j.jconrel.2015.01.011.
101. Tansi F, Kallweit E, Kaether C, Kappe K, Schumann C, Hilger I, et al. Internalization of near-infrared fluorescently labeled activatable cell-penetrating peptide and of proteins into human fibrosarcoma cell line HT-1080. Journal of Cellular Biochemistry 2014. doi: 10.1002/jcb.25075.
102. LeBeau AM, Denmeade SR. Protease-Activated Pore-Forming Peptides for the Treatment and Imaging of Prostate Cancer. Mol Cancer Ther. 2014 Dec 23. doi: 10.1158/1535-7163.